LONDON (Alliance News) - NetScientific PLC Friday said its Glycotest Inc portfolio company has entered into a collaboration agreement with Oncimmune Ltd.
Under the agreement, the pair will work on the combined application of their tests for the early detection of liver cancer, NetScientific said.
Oncimmune has commercialised its antibody assay technology previously for the early detection of lung cancer and is now expanding this test to liver cancer and other solid tumours. Glycotest is developing glycoprotein biomarkers and assay technology for detecting serious liver diseases, including liver cancer.
The two will conduct a joint clinical evaluation of the combined tests, which may then be co-developed.
"Today's announcement marks a key point in the validation of the Glycotest technology from the wider scientific community, and mirrors our statement at the recent half year results, that our subsidiaries are making significant progress," said NetScientific Chairman Richard Sykes.
By Sam Unsted; firstname.lastname@example.org; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.